You are here
P&T July 2018
Quiet changes in federal health programs make minor but significant consumer-friendly changes in the way drugs are priced for seniors in 2019. The author considers how this lays the groundwork for more radical changes in the future.
The authors discuss the diagnosis, the role of chemotherapy, and the role of emerging therapies in the treatment of metastatic soft tissue sarcoma.
This article reviews the clinical data concerning the uses of hydroxyurea, L-glutamine, and crizanlizumab in treating pain crises associated with sickle cell disease.
Health care professionals report greater satisfaction with their time demands and the perceived accuracy of medication histories after the addition of pharmacy technicians to the medication reconciliation process in the ED at two large hospitals.
We report on sessions on immunotherapies for non–small-cell lung cancer and pancreatic cancer from AACR.
Endometriosis, hypoactive sexual desire disorder, neonatal abstinence syndrome, and more from ACOG.
Preventing incidents of oral meds given intravenously
Hospitals search for IV opioids
Approvals, new indications, regulatory activities, and more
Fostamatinib (Tavalisse) for thrombocytopenia in adults with chronic immune thrombocytopenia; coagulation factor Xa (recombinant), inactivated-zhzo (Andexxa) for the reversal of anticoagulation; epoetin alfa-epbx (Retacrit), a biosimilar for the treatment of anemia
Etelcalcetide (Parsabiv) for hyperparathyroidism in adults with chronic kidney disease on hemodialysis